(fifthQuint)A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age.

 Participants will be randomized to receive one dose of either High-Dose Trivalent Inactivated Influenza Vaccine or Trivalent Inactivated Influenza Vaccine.

 They will be followed up for safety for one month post-vaccination.

.

 A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age@highlight

The aim of the study is to generate data on key parameters associated with assessment of influenza vaccines in individuals 50-64 years of age Primary Objective: - To describe the immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine (TIV) compared to TIV.

 - To describe the safety profile of High-Dose Trivalent Inactivated Influenza Vaccine, as assessed by solicited adverse reactions collected for 7 days post-vaccination, and unsolicited adverse events (including Serious Adverse Events and Adverse Events of Special Interests) collected between Visit 1 and Visit 2